|
|
Phase II Randomized Study of Recombinant Fowlpox and Vaccinia Viruses Encoding Tyrosinase Antigen in Patients With Metastatic Melanoma
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Basic Trial Information
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
16 and over
|
|
|
|
NCI
|
|
|
|
NCI-99-C-0095 NCI-T99-0025, T99-0025, NCT00019734
|
|
|
Special Category:
NIH Clinical Center trial Objectives - Determine efficacy of recombinant fowlpox and vaccinia viruses encoding tyrosinase antigen, administered with or without low-dose interleukin-2 (IL-2), in terms of response, in patients with metastatic melanoma.
- Compare the response rate in patients to this vaccination administered with high-dose IL-2 to that in similar patients on previous trials treated with high-dose IL-2 alone.
- Determine the immunological response in patients treated with this regimen.
Entry Criteria Disease Characteristics:
- Histologically confirmed metastatic melanoma that has failed standard
treatment
- No ocular or mucosal melanoma as primary site
- Measurable disease
- No existing brain metastases
Prior/Concurrent Therapy:
Biologic therapy: - No prior recombinant vaccinia or fowlpox vaccines for
melanoma
- At least 3 weeks since prior systemic biologic therapy for
melanoma
Chemotherapy: - At least 3 weeks since prior systemic chemotherapy for
melanoma
Endocrine therapy: - At least 3 weeks since prior systemic endocrine therapy for
melanoma
- No concurrent steroid therapy
Radiotherapy: - At least 3 weeks since prior systemic radiotherapy for
melanoma
Surgery: Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - WBC at least 3,000/mm3
- Platelet count at least 90,000/mm3
- No coagulation disorder
Hepatic: - Bilirubin no greater than 1.6 mg/dL
- AST/ALT less than 3 times normal
- Hepatitis B surface antigen negative
Renal: - Creatinine no greater than 1.6 mg/dL
Cardiovascular: - No major cardiovascular illness
Pulmonary: - No major respiratory illness
Immunologic: - HIV negative
- No autoimmune disease
- No primary or secondary immunodeficiency
- No allergy to eggs
- No history of allergy or untoward reaction to prior smallpox
vaccination
Other: - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Must be able to avoid close contact with children under 5
years, pregnant women, people with active or a past history of eczema or
other eczematoid skin disorders, and immunosuppressed people for at least 2
weeks after each vaccinia virus vaccination
- No active systemic infections
- No active atopic dermatitis or active or past history of
eczema
- No concurrent active extensive psoriasis, severe acneiform
rash, impetigo, varicella zoster, burns, or other traumatic or pruritic skin
conditions or open wounds
- Surgical scars must be healed
- Healed surgical stomas (e.g., colostomy) allowed
Expected Enrollment A total of 73 patients (13-20 for arm I, 13-20 for arm II, and 19-33 for arm
III) will be accrued for this study within 2 years. Outline This is a randomized study. Patients are randomized to one of three
treatment arms. - Arm I: Patients receive recombinant fowlpox vaccine IM on day 1
followed 4 weeks later by recombinant vaccinia vaccine IM. Treatment repeats
for a minimum of 4 vaccinations.
- Arm II: Patients receive vaccinations as in arm I plus low-dose
interleukin-2 (IL-2) subcutaneously daily on days 2-13 after each
vaccination.
- Arm III: Patients receive vaccinations as in arm I plus high-dose IL-2
IV over 15 minutes every 8 hours on days 2-5 after each vaccination.
Patients with stable disease or a minor, mixed, or partial response
after four immunizations (1 course) may receive a second course of the same
regimen beginning 4-6 weeks after the first course. After the second course,
patients with tumor regression may continue to receive treatment in the
absence of unacceptable toxicity until best response is achieved. Patients are followed at 4-6 weeks.
Trial Contact Information
Trial Lead Organizations NCI - Center for Cancer Research | | | Suzanne Topalian, MD, Protocol chair(Contact information may not be current) | | | |
Registry Information | | Official Title | | Immunization of Patients with Metastatic Melanoma Using Recombinant Fowlpox and Vaccinia Viruses Encoding the Tyrosinase Antigen | | Trial Start Date | | 1999-07-19 | | Registered in ClinicalTrials.gov | | NCT00019734 | | Date Submitted to PDQ | | 1999-05-07 | | Information Last Verified | | 2007-05-31 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|